Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma

PD-1 blockade enhances the function of antitumor T cells and antibody-dependent, cell-mediated cytotoxicity (ADCC) of NK cells. In a single-center, open-label, phase 2 trial, we tested the combination of pembrolizumab, an anti-PD-1 monoclonal antibody, and rituximab, an anti-CD20 monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Nastoupil, Loretta J., Chin, Collin K., Westin, Jason R., Fowler, Nathan H., Samaniego, Felipe, Cheng, Xiaoyun, Ma, Man Chun John, Wang, Zhiqiang, Chu, Fuliang, Dsouza, Ly, Obi, Chizobam, Mims, Jennifer, Feng, Lei, Zhou, Shouhao, Green, Michael, Davis, Richard Eric, Neelapu, Sattva S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864656/
https://www.ncbi.nlm.nih.gov/pubmed/35015819
http://dx.doi.org/10.1182/bloodadvances.2021006240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864656/
https://www.ncbi.nlm.nih.gov/pubmed/35015819
http://dx.doi.org/10.1182/bloodadvances.2021006240

Ejemplares similares